Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
NCT03810183 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2021-10-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Company decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGDR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-31Results posted on the registry: Boehringer Ingelheim, BI 671800 + Fluticasone propionate placebo (NCT01092143)
- 2022-05-31Results posted on the registry: Boehringer Ingelheim, BI 671800 + Placebo (NCT01103349)
- 2022-05-11Results posted on the registry: Boehringer Ingelheim, BI 671800 + Placebo (NCT01090024)
- 2021-10-11Also stopped (terminated): Novartis Pharmaceuticals, Placebo once daily + QAW039 150 mg once daily (NCT03629249)
- 2021-05-03Results posted on the registry: Novartis Pharmaceuticals, QAW039 + QAW039 (NCT02563067)
- 2021-02-02Results posted on the registry: Novartis Pharmaceuticals, Placebo once daily + QAW039 150 mg once daily (NCT03629249)
- 2021-01-05Results posted on the registry: Novartis Pharmaceuticals, Fevipiprant 150 mg + Fevipiprant 450 mg (NCT03681093)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, QAV680 + QAV680 Placebo (NCT01103037)
- 2020-10-12Results posted on the registry: Novartis Pharmaceuticals, QAW039 150 mg + QAW039 450 mg (NCT03052517)
- 2020-10-12Also stopped (terminated): Novartis Pharmaceuticals, QAW039 150 mg + QAW039 450 mg (NCT03052517)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision